Compare AMPH & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPH | GHRS |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.8M | 947.2M |
| IPO Year | 2005 | 2021 |
| Metric | AMPH | GHRS |
|---|---|---|
| Price | $17.30 | $21.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $28.38 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 466.6K | 255.6K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $719,887,000.00 | N/A |
| Revenue This Year | $6.90 | N/A |
| Revenue Next Year | $4.64 | N/A |
| P/E Ratio | $131.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.03 | $9.52 |
| 52 Week High | $31.26 | $24.66 |
| Indicator | AMPH | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 30.67 | 61.88 |
| Support Level | $17.03 | $12.29 |
| Resistance Level | $20.08 | $24.66 |
| Average True Range (ATR) | 0.80 | 1.26 |
| MACD | -0.48 | -0.02 |
| Stochastic Oscillator | 2.19 | 67.11 |
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.